Scarica l'app Stockscreener
71.65
0.47%
-0.34
Dopo l'orario di chiusura:
73.05
1.40
+1.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$71.99
Aprire:
$72.42
Volume 24 ore:
400.42K
Relative Volume:
0.71
Capitalizzazione di mercato:
$2.70B
Reddito:
-
Utile/perdita netta:
$-91.00M
Rapporto P/E:
-19.52
EPS:
-3.67
Flusso di cassa netto:
$-74.38M
1 W Prestazione:
-8.53%
1M Prestazione:
-9.33%
6M Prestazione:
+21.38%
1 anno Prestazione:
+33.58%
Intervallo 1D:
$70.60
$73.67
Intervallo di 1 settimana:
$70.60
$81.28
Portata 52W:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
71.65 | 2.72B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
getLinesFromResByArray error: size == 0 - mfd.ru
Hedge Fund Bets: Whats the beta of Disc Medicine Inc stockJuly 2025 Action & Entry Point Confirmation Alerts - baoquankhu1.vn
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - ChartMill
Trend Review: Will Disc Medicine Inc outperform during market rallies2025 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Responsive Playbooks and the IRON Inflection - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - accessnewswire.com
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BMO Capital reaffirms Disc Medicine stock rating amid approval optimism By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Investors to Inquire about Securities Investigation - accessnewswire.com
Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade - Yahoo Finance
Disc Medicine, Inc. (IRON) Stock Analysis: Biotech Innovator With A 57% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Investors to Reach Out - ACCESS Newswire
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst - streetwisereports.com
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON - Chartmill
Bear Alert: What is Disc Medicine Inc. s debt to equity ratioJuly 2025 Catalysts & Accurate Intraday Trade Tips - baoquankhu1.vn
HC Wainwright Weighs in on Disc Medicine FY2030 Earnings - MarketBeat
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
iA Global Asset Management Inc. Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Understanding the Setup: (IRON) and Scalable Risk - Stock Traders Daily
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock - MarketBeat
The Bull Case For Disc Medicine (IRON) Could Change Following FDA Review Delay And New HR Chief Appointment - Sahm
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Is Disc Medicine Inc. attractive at current valuationWeekly Market Outlook & High Win Rate Trade Alerts - bollywoodhelpline.com
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus - Sahm
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON) - The Globe and Mail
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA ActionDisc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
Reported delays to FDA reviews under new fast-track program - The Pharma Letter
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com South Africa
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Disc Medicine Inc Azioni (IRON) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khara Rahul | Chief Legal Officer |
Jan 20 '26 |
Sale |
69.74 |
1,000 |
69,740 |
37,793 |
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Option Exercise |
13.50 |
6,500 |
87,750 |
44,293 |
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Sale |
78.69 |
6,500 |
511,472 |
37,793 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):